Elyse G. Seltzer
Corporate Officer/Principal at Yale University
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Gelone | M | 56 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 10 years |
| Dong Kim | M | 47 | 3 years | |
| Phil Thomson | M | - | 13 years | |
| Daniel Burgess | M | 62 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 8 years |
| Emma Walmsley | F | 55 | 14 years | |
| Elizabeth Barrett | F | 62 | 5 years | |
| Urs Rohner | M | 65 | 9 years | |
| Lei Zhang | M | 51 |
Yale University
| - |
| Richard Levin | M | 77 |
Yale University
| 31 years |
| Richard Foster | M | 82 |
Yale University
| - |
| Ari Helenius | M | - |
Yale University
| 41 years |
| Radha Kuppalli | F | - |
Yale University
| 16 years |
| Jason Smith | M | 52 | 4 years | |
| Steven Alan Orszag | M | - |
Yale University
| - |
| Alexandros Makridis | M | 62 |
Yale University
| - |
| Denny Sakkas | M | - |
Yale University
| - |
| Stephen Winter | M | - |
Yale University
| - |
| Robert J. Shiller | M | - |
Yale University
| - |
| Kyle Pruett | M | - |
Yale University
| - |
| Ali K. Riba | M | - |
Yale University
| 20 years |
| Robert Schwartz | M | - |
Yale University
| 20 years |
| Hernando José Gómez Restrepo | M | 67 |
Yale University
| - |
| Marlene Beth Schwartz | M | - |
Yale University
| - |
| Michael Warren | M | 56 |
Yale University
| - |
| Michael Northrop | M | - |
Yale University
| - |
| Steve Blum | M | 72 |
Yale University
| - |
| Hyuk-Jeen Suh | M | - |
Yale University
| 4 years |
| Christopher di Bonaventura | M | - |
Yale University
| - |
| Melanie Ginter | F | - |
Yale University
| - |
| Martha Woodcock | F | - |
Yale University
| - |
| Eileen Donahue | F | - |
Yale University
| - |
| Rishay Patel | M | - |
Yale University
| 3 years |
| Joseph F. Renzulli | M | - |
Yale University
| - |
| Paul T. Anastas | M | - |
Yale University
| - |
| Louise M. Dembry | M | - |
Yale University
| 31 years |
| Daniel C. Esty | M | - |
Yale University
| - |
| John Puziss | M | - |
Yale University
| 23 years |
| Stephen Kieran | M | - |
Yale University
| - |
| Sandra A. Carson | M | 70 |
Yale University
| - |
| Jaime Gerber | M | - |
Yale University
| 11 years |
| Sean T. Dixon | M | - |
Yale University
| - |
| Stanley McChrystal | M | 69 |
Yale University
| - |
| Stephen L. Carter | M | - |
Yale University
| - |
| Joanne B. Weidhaas | M | - |
Yale University
| - |
| James Gustave Speth | M | - |
Yale University
| - |
| David Nierenberg | M | 70 |
Yale University
| - |
| Amy Wrzesniewski | M | - |
Yale University
| - |
| Joseph A. Madri | M | 80 |
Yale University
| 44 years |
| Jeffrey Bewkes | M | 71 |
Yale University
| - |
| Leon E. Rosenberg | M | 90 |
Yale University
| 25 years |
| Vincent Marchesi | M | 88 |
Yale University
| 51 years |
| Ernesto Zedillo Ponce de León | M | 71 |
Yale University
| 22 years |
| David I. Scheer | M | 71 |
Yale University
| - |
| Henry George Jarecki | M | - |
Yale University
| - |
| Alan G. Schwartz | M | 84 |
Yale University
| 37 years |
| Gerard N. Burrow | M | - |
Yale University
| - |
| Lauren Zucker | F | 54 |
Yale University
| 13 years |
| Roland Hernandez | M | 65 |
Yale University
| - |
| Donald M. Engelman | M | 83 |
Yale University
| 45 years |
| Douglas Warner | M | 77 |
Yale University
| - |
| William Miller | M | 67 |
Yale University
| - |
| Michael Jerome Hawley | M | 62 |
Yale University
| - |
| James Tananbaum | M | 59 |
Yale University
| - |
| Jeff Miller | M | 75 |
Yale University
| - |
| Tom Glocer | M | 63 |
Yale University
| - |
| David Sze | M | 58 |
Yale University
| - |
| John Deno Geanakoplos | M | 68 |
Yale University
| 38 years |
| Viswanathan Vinay | M | - |
Yale University
| - |
| Kathleen E. Walsh | F | 68 |
Yale University
| - |
| Linda Mason | F | 69 |
Yale University
| - |
| Martin H. Schultz | M | - |
Yale University
| - |
| Joan Dea | F | 60 |
Yale University
| - |
| Jonathan R. Macey | M | 68 |
Yale University
| - |
| Vincent Pieribone | M | - |
Yale University
| - |
| Patricia Sue Fitzsimons | M | - |
Yale University
| - |
| Brad Huang | M | 59 |
Yale University
| - |
| Paul Bracken | M | - |
Yale University
| - |
| Thomas Conley | M | - |
Yale University
| - |
| Harry Ballan | M | - |
Yale University
| - |
| Ralph E. Grossi | M | - |
Yale University
| - |
| E. Jonathan Soderstrom | M | 69 |
Yale University
| - |
| Edward F. Zigler | M | - |
Yale University
| - |
| Alvin K. Klevorick | M | - |
Yale University
| - |
| Peter Moore | M | - |
Yale University
| - |
| Kenneth V. Schwartz | M | - |
Yale University
| - |
| Barry J. Nalebuff | M | - |
Yale University
| - |
| Mark Velleca | M | 60 |
Yale University
| - |
| Frances G. Beinecke | F | - |
Yale University
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Garrett | M | 44 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | - |
| Robert L. Crotty | M | 50 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | - |
| Peter Pfreundschuh | M | 55 | 2 years | |
| Mark Corrigan | M | 66 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 4 years |
| Gary Sender | M | 62 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 7 years |
| Philip Hampton | M | 70 | 4 years | |
| Ralf Schmid | M | 57 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 10 years |
| Mark Stejbach | M | 61 | 4 years | |
| George Harrison Talbot | M | 76 |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | 12 years |
| Joseph W. la Barge | M | 53 | 5 years | |
| Gil Hakim | M | 54 | 8 years | |
| Thomas Mount | M | - | 7 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 88 | 88.00% |
| Austria | 8 | 8.00% |
| United Kingdom | 5 | 5.00% |
| Ireland | 5 | 5.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elyse G. Seltzer
- Personal Network
